Editas Medicine (EDIT) Institutional Ownership

During the previous two years, 152 institutional investors and hedge funds held shares of Editas Medicine. The most heavily invested institutionals were Vanguard Group Inc. ($63.48M), Deep Track Capital LP ($28.42M), State Street Corp ($8.40M), Ghisallo Capital Management LLC ($8.02M), Pictet Asset Management SA ($7.66M), Credit Suisse AG ($7.09M), and Rafferty Asset Management LLC ($4.14M).Learn more on EDIT's institutional investors.

71.90% of Editas Medicine stock is owned by institutional investors. Learn more on EDIT's institutional investor holdings.

Of the 128 institutional investors that purchased Editas Medicine stock in the last 24 months, the following investors and hedge funds have bought the highest volume of shares: Deep Track Capital LP ($3.45M), Marshall Wace LLP ($2.84M), Renaissance Technologies LLC ($1.45M), Balyasny Asset Management L.P. ($1.13M), Monaco Asset Management SAM ($1.07M), Ghisallo Capital Management LLC ($974.62K), and Pictet Asset Management SA ($808.30K).

Institutional investors have bought a total of 23,467,096 shares in the last 24 months. This purchase volume represents approximately $130.41M in transactions.

Of the 56 institutional investors that sold Editas Medicine stock in the last 24 months, the following investors and hedge funds have sold the highest volume of shares: State Street Corp ($2.13M), Renaissance Technologies LLC ($799.99K), Millennium Management LLC ($603.77K), BNP Paribas Financial Markets ($465.06K), Bank of America Corp DE ($449.07K), Citigroup Inc. ($445.42K), and Dimensional Fund Advisors LP ($370.31K).

Institutional investors have sold a total of 8,774,025 shares in the last 24 months. This volume of shares sold represents approximately $38.71M in transactions.